Return
Management of cancer-associated thrombosis in patients with gastrointestinal cancers: lights and shadows
L
E
N
C
A
N
DOI:10.1016/j.ctrv.2026.103180.png)
Abstract
En 中文
• GI cancers show marked heterogeneity in VTE risk by site, stage, and treatment • Current risk models inadequately capture CAT risk in GI malignancies • Prophylaxis strategies must balance high thrombotic and bleeding risks in GI tumors • DOAC safety varies across GI cancer subtypes, with caution in upper GI tumors • Molecular profiling and ctDNA may improve individualized CAT risk stratification
Journal
IF:
10.5
Papers:
2.8K
Citations:
1.3W
